SecBot SecBot
Biotech Drug Report Generated Nov 19, 2026

VABOMERE

CRMD·CorMedix Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed (FDA approved August 2017). Currently commercialized in the U.S. and Canada.
Why 4/10
VABOMERE is an already-approved, marketed drug with no pending regulatory decision or pivotal readout specific to this product in the next ~12 months. The next hard catalyst for CorMedix overall is the REZZAYO sNDA PDUFA (not VABOMERE). VABOMERE is one of several products in a diversified portfolio, so its individual impact on the stock is limited.
Actionable Insight NEUTRAL

VABOMERE is an approved, marketed product with no imminent binary catalyst of its own. The next major catalyst for CorMedix overall is the FDA decision on the REZZAYO sNDA (accepted for Priority Review in October 2026, PDUFA expected in early 2027). Watch for the Phase 2 pediatric study (NCT06672978) primary completion around January 2027, which could support a label expansion for VABOMERE into children, though this is a secondary pipeline item.

Price Chart

Loading chart...

Executive Summary

VABOMERE (meropenem and vaborbactam) is an FDA-approved IV antibiotic for complicated urinary tract infections, originally approved in August 2017 for The Medicines Company. It is now owned by CorMedix (CRMD) through the company's $300M acquisition of Melinta Therapeutics in September 2025, which added seven marketed products to CorMedix's portfolio. VABOMERE is a mature, commercial-stage product with no imminent binary catalyst of its own. CorMedix's primary growth driver remains DefenCath, with the next major catalyst being the REZZAYO sNDA for prophylaxis of invasive fungal disease (accepted for Priority Review in October 2026). CorMedix guided FY2026 revenue of $325M-$345M and recently announced a $145M+ acquisition of Heron Therapeutics assets.

How It Works

VABOMERE is an intravenous antibiotic that combines two drugs: meropenem (a broad-spectrum carbapenem antibiotic that kills bacteria by disrupting their cell wall construction) and vaborbactam (a beta-lactamase inhibitor that protects meropenem from being broken down by resistant bacteria). It is used to treat complicated urinary tract infections, including kidney infections, caused by certain drug-resistant bacteria.

Trial Status

VABOMERE is FDA-approved and commercially marketed. A Phase 2 pediatric study (NCT06672978) evaluating meropenem-vaborbactam in children with complicated UTI is active but not recruiting, with estimated primary completion in January 2027. The study is sponsored by Rempex (a Melinta subsidiary).

The Two-Sided Case

▲ Bull Case4
VABOMERE is an FDA-approved IV antibiotic with a differentiated mechanism (meropenem + beta-lactamase inhibitor vaborbactam) for serious Gram-negative infections, addressing an area of high unmet need.
CorMedix now has a diversified portfolio of 7+ marketed hospital products (including VABOMERE) following the Melinta acquisition, reducing single-product risk.
A Phase 2 pediatric study (NCT06672978) is active with estimated primary completion in January 2027, which could support label expansion into children with cUTI.
CorMedix guided FY2026 revenue of $325M-$345M, and analysts see 205% upside to the mean price target of $13.80. Insiders (CEO and a director) recently bought shares at ~$4.88-$4.89.
▼ Bear Case4
VABOMERE faces generic/biosimilar competition in the antibiotic market; meropenem alone is widely available as a generic.
VABOMERE is one of many products in CorMedix's portfolio and is not a primary growth driver; the company's revenue is still heavily dependent on DefenCath, which faces TDAPA reimbursement headwinds.
CorMedix stock has fallen sharply from its 52-week high of $13.02 to ~$4.55, and elevated short-sale volume (z-score 2.82 vs the stock's own history) suggests bearish positioning.
The company is executing multiple large acquisitions (Melinta for $300M, Heron assets for $145M+), creating integration risk and potential dilution.

Upcoming Catalysts

  • Phase 2 pediatric study (NCT06672978) primary completion estimated January 2027, could support pediatric label expansion
  • REZZAYO sNDA PDUFA decision (Priority Review accepted October 2026, decision expected early 2027) - the next major company-wide catalyst, though not specific to VABOMERE

Source Filing

The SecBot filing or press-release report that triggered this drug report:

CorMedix Inc. DEFA14A CRMD ·Originating report

Sources · 8

Hover a chip for the title
1 businesswire.com2 streetinsider.com3 nasdaq.com4 biospace.com5 msn.com6 seekingalpha.com7 finanznachrichten.de8 fiercepharma.com